omniture

Tiens Biotech Group (USA) Reports Third Quarter Results

2007-11-15 13:59 454


NEW YORK, Nov. 15 /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA), Inc. ("the Company" or "Tiens"), (Amex: TBV), http://www.tiens-bio.com , announced financial results for the third quarter ended September 30, 2007.

Revenue for the third quarter of 2007 was $11.0 million compared to $19.2 million for the third quarter of 2006.

Net income for the third quarter of 2007 was $3.1 million, or $0.04 per share, compared to net income of $8.4 million, or $0.12 per share for the third quarter of 2006.

Revenue for the nine months ended September 30, 2007 was $41.6 million, compared to $50.2 million for the nine months ended September 30, 2006.

Net income for the nine months ended September 30, 2007 was $14.7 million, or $0.21 per share, compared to $20.4 million, or $0.29 per share for the same period in 2006.

Revenue by Region

For the third quarter of 2007, revenue in China was $3.4 million compared to $7.2 million for the third quarter of 2006. For the nine months ended September 30, 2007, revenue in China was $15.7 million, compared to $20.3 million for the nine months ended September 30, 2006.

Revenue for the third quarter of 2006 benefited from a special promotion conducted for distributors in China. No similar promotion was held during the third quarter of 2007, which contributed to the decrease in revenue for the period. Sales in China were also negatively impacted by increased government and media scrutiny on the direct selling industry, which the Company intends to pursue through its distributor in China, particularly following the enactment of the new direct selling regulations.

For the third quarter of 2007, international revenue was $7.6 million, compared to $11.9 million for the third quarter of 2006. For the nine months ended September 30, 2007, international revenue was $25.8 million, compared to $29.9 million for the first nine months of 2006.

In August of 2007, the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) announced an ongoing national campaign in China against unsafe food and substandard products. The four-month special campaign against poor product quality was launched in response to a series of safety issues involving Chinese products worldwide. The campaign, which is currently scheduled to run to the end of the year, set detailed goals including the licensing of all food producers, monitoring of agricultural wholesale markets in all cities, inspection of suppliers of raw materials for exported products and assuring that agricultural products be free of five types of strong pesticides.

As a result of this campaign by the AQSIQ, there has been a general

slow-down and backlog of export clearances for Chinese food products, which has resulted in Tiens experiencing significant delays in obtaining export clearance for its products, which are sold to its international affiliates. These delays have resulted in decreases in international revenues and several of Tiens' international affiliates being unable to receive sufficient quantities of products to meet their demand. However, to date, no problems have been identified with any of Tiens' products.

Other Highlights

Cost of sales for the third quarter of 2007 decreased to $3.1 million, or 39%, compared to $5.1 million for the same period in 2006. This decrease was primarily due to the corresponding decrease in revenue. Cost of sales for the nine months ended September 30, 2007 was $12.0 million, compared to $13.7 million for the same period in 2006, a decrease of 12.7%.

Gross profit for the third quarter of 2007 was $7.9 million compared to $14.1 million for the same period in 2006. The gross profit margin for the third quarter of 2007 was 72.0%, compared to 73.6% for the same period in 2006. Gross profit for the nine months ended September 30, 2007 was $29.6 million, compared to $36.5 million for the same period in 2006. The gross profit margin for the nine months ended September 30, 2007 was 71.2%, compared to 72.7% for the same period in 2006. These decreases reflect reductions in revenue for the third quarter and first nine months of 2007 and gross profit margins being lower for semi-finished products than for the finished products that the Company was still selling in 2006.

Selling, general and administrative expenses increased to $3.8 million for the third quarter of 2007, compared to $2.8 million for the same period in 2006. The selling and administrative expense as a percentage of sales was 34.5% for the third quarter of 2007 compared to 14.6% for the same period in 2006. Selling, general and administrative expenses were $10.4 million for the nine months ended September 30, 2007, compared to $8.6 million for the same period in 2006. The selling and administrative expense as a percentage of sales was 24.9% for the nine months ended September 30, 2007 compared to 17.2% for the same period in 2006. The increase in expenses reflect an increase in salary and depreciation expenses, and the increase in expenses as a percentage of sales was also due to the aforementioned decrease in sales.

As of September 30, 2007, Tiens had $110 million of retained earnings and total shareholders' equity of $139 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, "The current quarter reflects the challenges of the direct selling environment in China and exporting internationally. While there has been a general slow-down and backlog of export clearances for Chinese food items, we remain dedicated to maintaining the high quality of our products which have met all regulatory scrutiny. We will continue to strive to expand our market share in China and further establish the Tiens brand internationally."

About Tiens Biotech Group (USA), Inc. http://www.tiens-bio.com

Tiens Biotech Group (USA), Inc. (Amex: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary nutrition supplement products, and personal care products.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 63 countries. Since its establishment, Tiens has developed and produced 35 nutrition supplements, which include wellness products and dietary nutrition supplements. Tiens develops its products at its own product research and development center, which employs highly qualified professionals in the fields of pharmacology, biology, chemistry and fine chemistry. Tiens has obtained all required certificates and approvals from government regulatory agencies to manufacture and sell its products in China.

In China, Tiens conducts the marketing and sales of its products through its affiliated company, Tianshi Engineering. Tianshi Engineering markets and sells Tiens' products in China through chain stores, domestic affiliated companies, and its 105 branches. Outside of China, Tiens sells its products to affiliated companies in 63 countries who in turn sell through an extensive direct sales force, or multi-level marketing sales force. The Company's direct sales marketing program is subject to governmental regulation in each of these countries.

Certain statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such

forward-looking statements are not necessarily indicative of future financial results, and may involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to: (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) whether the Company continues to experience delays in the export clearance of its products; (v) whether Tianshi Engineering, the Company's affiliate which sells its products in China, obtains a direct selling license in China; and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov under "Search for Company Filings."

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME

FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006

(Unaudited)

Three months ended Nine months ended

September 30 September 30

2007 2006 2007 2006

REVENUE - RELATED

PARTIES $11,027,478 $19,187,748 $41,584,749 $50,203,306

COST OF SALES 3,089,791 5,066,051 11,979,984 13,714,739

GROSS PROFIT 7,937,687 14,121,697 29,604,765 36,488,567

SELLING, GENERAL AND

ADMINISTRATIVE

EXPENSES 3,801,914 2,803,859 10,353,397 8,641,512

INCOME FROM OPERATIONS 4,135,773 11,317,838 19,251,368 27,847,055

OTHER INCOME, NET 149,683 164,104 1,044,290 127,458

INCOME BEFORE

PROVISION FOR INCOME

TAXES AND MINORITY

INTEREST 4,285,456 11,481,942 20,295,658 27,974,513

PROVISION FOR INCOME

TAXES 344,248 878,931 1,610,653 2,188,491

INCOME BEFORE MINORITY

INTEREST 3,941,208 10,603,011 18,685,005 25,786,022

MINORITY INTEREST 848,212 2,167,747 3,970,791 5,396,570

NET INCOME 3,092,996 8,435,264 14,714,214 20,389,452

OTHER COMPREHENSIVE

INCOME

Foreign currency

translation

adjustment 1,593,144 1,411,012 4,930,487 2,396,799

COMPREHENSIVE INCOME $4,686,140 $9,846,276 $19,644,701 $22,786,251

EARNINGS PER SHARE,

BASIC AND DILUTED $0.04 $0.12 $0.21 $0.29

WEIGHTED AVERAGE

NUMBER OF SHARES 71,333,586 71,333,586 71,333,586 71,333,586

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF SEPTEMBER 30, 2007 AND DECEMBER 31, 2006

A S S E T S

September 30, December 31,

2007 2006

(Unaudited)

CURRENT ASSETS:

Cash $51,841,201 $54,270,065

Accounts receivable, trade -

related parties, net of allowance

for doubtful accounts of $75,456

and $86,776 as of September 30, 2007

and December 31, 2006, respectively 15,015,659 12,926,670

Accounts receivable, trade - third

parties 18,817 18,135

Inventories 5,635,349 6,845,108

Other receivables 568,693 349,905

Other receivables - related parties 18,573,926 8,397,227

Employee advances 85,716 111,121

Prepaid expense 1,286,639 2,135,917

Loans receivable 3,497,238 3,223,809

Loans receivable - related party 27,714,328 25,640,000

Total current assets 124,237,566 113,917,957

Property, PLANT AND EQUIPMENT, net 34,205,418 30,511,319

OTHER ASSETS:

Intangible assets, net 3,061,331 510,183

Long-term prepaid expenses 1,629,810 3,807,539

Total other assets 4,691,141 4,317,722

Total assets $163,134,125 $148,746,998

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF SEPTEMBER 30, 2007 AND DECEMBER 31, 2006

L I A B I L I T I E S A N D S H A R E H O L D E R S' E Q U I T Y

September 30, December 31,

2007 2006

(Unaudited)

CURRENT LIABILITIES:

Accounts payable $2,954,969 $4,123,105

Advances from customers -

related parties 1,564,869 1,570,120

Wages and benefits payable 788,545 992,068

Other taxes payable 652,815 969,760

Other payables 630,328 500,213

Other payables - related

parties 252,728 522,105

Dividend payable to minority

interest 256,583 238,311

Current portion of long term

debt, related party 2,130,000 2,130,000

Total current

liabilities 9,230,837 11,045,682

LONG TERM DEBT, net of current

portion, related party 5,332,742 6,397,742

Total liabilities 14,563,579 17,443,424

MINORITY INTEREST 9,505,594 11,883,323

SHAREHOLDERS' EQUITY:

Common stock, $0.001 par

value, 260,000,000 shares

authorized, 71,333,586

issued and outstanding,

respectively 71,334 71,334

Paid-in-capital 8,842,009 8,842,009

Statutory reserves 9,420,783 9,420,783

Retained earnings 110,085,351 95,371,137

Accumulated other

comprehensive income 10,645,475 5,714,988

Total shareholders'

equity 139,064,952 119,420,251

Total liabilities and

shareholders' equity $163,134,125 $148,746,998

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES

REVENUE BY REGION

(Unaudited)

Three months

ended September 30,

2007 2006 Change

China $3,388,880 $7,240,485 -53.2%

International $7,638,589 $11,947,263 -36.1%

Total $11,027,478 $19,187,748 -42.5%

Nine months

ended September 30,

2007 2006 Change

China $15,736,494 $20,281,510 -22.4%

International $25,848,255 $29,921,796 -13.6%

Total $41,584,749 $50,203,306 -17.2%

For more information, please contact:

Tiens Biotech Group (USA), Inc.

Tel: +86-22-8213-7915

Fax: +86-22-8213-7667

Email: investor@tiens-bio.com

Web: http://www.tiens-bio.com

Carl Hymans

G. S. Schwartz & Co.

Tel: +1-212-725-4500

Fax: +1-212-725-9188

Email: carlh@schwartz.com

Source: Tiens Biotech Group (USA), Inc.
Related Stocks:
AMEX:TBV
collection